The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis.
 
Yuki Endo
Honoraria - Astellas Pharma; Merck; Nippon Kayaku
 
Yukihiro Kondo
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Nippon Kayaku
 
Yuma Sakura
No Relationships to Disclose
 
Go Kaneko
Honoraria - Astellas Pharma
 
Nozomi Hayakawa
Honoraria - Astellas Pharma; Daiichi Sankyo; Merck; Takeda
 
Daiki Ikarashi
No Relationships to Disclose
 
Ryo Yamashita
No Relationships to Disclose
 
Suguru Shirotake
Honoraria - Bristol-Myers Squibb; Eisai; Merck; MSD; Ono Pharmaceutical; Takeda
 
Wataru Obara
Honoraria - Astellas Pharma; AstraZeneca; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Ferring; Janssen; MSD; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Janssen; Kissei Pharmaceutical; Kyorin; Merck; MSD; Nippon Kayaku; Nippon Shinyaku; Pfizer; Sanofi; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)